FDA Adverse Event Malfunction Summary report: N

LUMIRADX SARS-COV-2 AG TEST STRIP KIT

MDR report key: 12416155 · Received September 2, 2021

Report

Report Number
3012642695-2021-01315
Event Type
Malfunction
Date Received
September 2, 2021
Date of Event
August 21, 2021
Report Date
September 2, 2021
Manufacturer
LUMIRADX UK LTD.
Product Code
QKP
Report Source
Manufacturer report
Reporter Location
UK
Reporter Occupation
OTHER

Narratives

Additional Manufacturer Narrative · 1

PATIENT WAS TESTED WITH LUMIRADX SARS-COV-2 AG TEST ON (B)(6) 2021 WITH STRIP LOT 6000409 AND INSTRUMENT SERIAL NUMBER (B)(4). CONFIRMATORY TESTING WAS PERFORMED VIA POLYMERASE CHAIN REACTION (PCR). THE CONFIRMATORY TEST RESULT WAS NEGATIVE. THE CUSTOMER REPORTED THEIR CLEANING PRACTICES TO BE "CLEAN BEFORE AND AFTER EACH PATIENT.", AND FURTHER REPORTED THAT GLOVES ARE CHANGED AFTER EACH SAMPLE. LOT 6000409 MET ALL DEFINED QC CRITERIA AT THE TIME IT WAS RELEASED AND TESTING USING NEGATIVE NASAL SWABS FROM IN-HOUSE DONORS MEETS EXPECTED PERFORMANCE FOR USE IN THE FIELD. NO SYMPTOMS WERE REPORTED FOR THIS PATIENT. THEREFORE, A REVIEW OF PRODUCT RISK ASSESSMENT - SARS-COV-2 AG ASSAY REVISION 7, RESULTED IN SEVERITY OF MINOR, AS FOLLOWS: ASYMPTOMATIC PATIENTS COULD EXPERIENCE SECONDARY HARM OF UNNECESSARY SELF ISOLATION AND POSSIBLE STRESS/ANXIETY. NO PATIENT HARM, INJURY OR ADVERSE HEALTH CONSEQUENCES WERE COMMUNICATED BY THE CUSTOMER TO LUMIRADX FOR THE REPORTED DISCORDANT RESULT. TRENDING DATA FOR DISCORDANT RESULTS WAS REVIEWED FOR THIS LOT AND THE OCCURRENCE RATE PER QUANTITY OF STRIPS IN THE FIELD WAS CALCULATED AS (B)(4). LUMIRADX SARS-COV-2 AG TEST PRODUCT INSERT CLAIMS A SPECIFICITY OF 96.6% WITH A REFERENCE RT-PCR ASSAY AND IT IS ACCEPTED THAT UP TO 3.4% OF TEST STRIPS MAY GENERATE A DISCORDANT FALSE POSITIVE RESULT. ROOT CAUSE DETERMINATION: NO DEFINITIVE ROOT CAUSE HAS BEEN DETERMINED FOR THE REPORTED DISCORDANT RESULT BASED ON THE INFORMATION CURRENTLY AVAILABLE. INVESTIGATION CONCLUSION AND STATUS OF INVESTIGATION: NO FURTHER INVESTIGATION IS CONSIDERED NECESSARY AT THIS TIME. THIS STRIP LOT CONTINUES TO DEMONSTRATE FIELD PERFORMANCE WITHIN SPECIFICATION OF PRODUCT CLAIMS RELATIVE TO THE QUANTITY OF STRIPS FROM THIS LOT IN THE FIELD. REPORTS OF DISCORDANT RESULTS FOR THIS LOT WILL CONTINUE TO BE TRENDED AND REVIEWED, WITH ACTION TAKEN AS APPROPRIATE IN RESPONSE TO ANY ADVERSE TRENDS OR EVENTS INCLUDING A FOLLOW-UP REPORT.

Description of Event or Problem · 1

THE CUSTOMER REPORTED A SUSPECTED FALSE (INCORRECT) POSITIVE RESULT FROM A RAPID RESULT COVID TEST SYSTEM ON AN INDIVIDUAL PATIENT.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1313578 LUMIRADX SARS-COV-2 AG TEST STRIP KIT CORONAVIRUS ANTIGEN DETECTION TEST SYSTEM, QKP LUMIRADX UK LTD. 6000409

Patients

Seq Age Sex Outcome Treatment
1